Amoy Diagnostics Co Ltd Asset Resilience Ratio
Amoy Diagnostics Co Ltd asset resilience ratio. Amoy Diagnostics Co Ltd (300685) has an Asset Resilience Ratio of 7.85% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Amoy Diagnostics Co Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Amoy Diagnostics Co Ltd (2018–2025)
Asset resilience ratio of Amoy Diagnostics Co Ltd from 2018 to 2025. This chart shows how Amoy Diagnostics Co Ltd's Asset Resilience Ratio has changed over time. See 300685 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Amoy Diagnostics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Amoy Diagnostics Co Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥173.83 Million | 7.85% |
| Total Liquid Assets | CN¥173.83 Million | 7.85% |
Asset Resilience Insights
- Limited Liquidity: Amoy Diagnostics Co Ltd maintains only 7.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Amoy Diagnostics Co Ltd Industry Peers by Asset Resilience Ratio
Compare Amoy Diagnostics Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Voxel S.A.
WAR:VOX |
Diagnostics & Research | 0.32% |
|
Leveljump Healthcare Corp
V:JUMP |
Diagnostics & Research | 32.45% |
|
Prodia Widyahusada Tbk PT
JK:PRDA |
Diagnostics & Research | 7.82% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Amoy Diagnostics Co Ltd Asset Resilience Ratio by Year (2018–2025)
Amoy Diagnostics Co Ltd asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Amoy Diagnostics Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.75% | CN¥275.96 Million ≈ $40.38 Million |
CN¥2.35 Billion ≈ $343.53 Million |
-5.29pp |
| 2024-12-31 | 17.04% | CN¥351.89 Million ≈ $51.49 Million |
CN¥2.06 Billion ≈ $302.15 Million |
-7.20pp |
| 2023-12-31 | 24.25% | CN¥469.12 Million ≈ $68.65 Million |
CN¥1.93 Billion ≈ $283.13 Million |
+8.54pp |
| 2022-12-31 | 15.71% | CN¥259.30 Million ≈ $37.94 Million |
CN¥1.65 Billion ≈ $241.58 Million |
-5.08pp |
| 2021-12-31 | 20.78% | CN¥315.85 Million ≈ $46.22 Million |
CN¥1.52 Billion ≈ $222.41 Million |
-2.80pp |
| 2020-12-31 | 23.58% | CN¥304.86 Million ≈ $44.61 Million |
CN¥1.29 Billion ≈ $189.19 Million |
+20.71pp |
| 2019-12-31 | 2.87% | CN¥30.06 Million ≈ $4.40 Million |
CN¥1.05 Billion ≈ $153.18 Million |
+2.86pp |
| 2018-12-31 | 0.01% | CN¥90.36K ≈ $13.22K |
CN¥818.75 Million ≈ $119.81 Million |
-- |
About Amoy Diagnostics Co Ltd
Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive … Read more